Can You Prescribe Bupropion and Atomoxetine Together for ADHD?
Yes, you can prescribe bupropion and atomoxetine concurrently for ADHD, but this is an off-label combination with limited evidence and should be reserved for specific clinical scenarios where monotherapy has failed. This combination is not FDA-approved and lacks robust clinical trial data, but there is some limited evidence supporting the use of atomoxetine in combination with other ADHD medications 1.
Evidence-Based Framework for Combination Therapy
First-Line Treatment Should Be Exhausted First
Before considering bupropion plus atomoxetine, you should have already tried:
- Stimulants (methylphenidate or amphetamines) as first-line monotherapy 1
- Atomoxetine monotherapy as a non-stimulant alternative 1
- FDA-approved adjunctive combinations: extended-release guanfacine or extended-release clonidine added to stimulants (these are the ONLY combinations with sufficient evidence and FDA approval for adjunctive use) 1
When This Combination Might Be Considered
The 2019 AAP guidelines explicitly state: "Other medications have been used in combination on an off-label basis, with some limited evidence available to support the efficacy and safety of using atomoxetine in combination with stimulant medications to augment treatment of ADHD" 1. While this refers to atomoxetine with stimulants, the principle of off-label combination use is acknowledged.
Bupropion plus atomoxetine might be considered when:
- Stimulants are contraindicated (cardiac risk factors, substance use disorder history, severe anxiety)
- Atomoxetine monotherapy provides partial response
- Comorbid depression exists (bupropion has antidepressant properties)
- Patient cannot tolerate stimulants or FDA-approved adjunctive agents
Critical Safety Considerations
Cardiovascular Monitoring is Mandatory
Both medications affect cardiovascular parameters:
- Atomoxetine increases heart rate and blood pressure 1
- Bupropion can also affect cardiovascular parameters
Before initiating either medication, you must:
- Obtain detailed personal and family cardiac history (sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome) 1
- Perform ECG if any risk factors are present 1
- Consider cardiology referral if ECG is abnormal 1
- Monitor heart rate and blood pressure regularly during treatment
Psychiatric Adverse Effects Require Close Monitoring
Atomoxetine carries an FDA black box warning for suicidal ideation in children and adolescents 2. The risk is 0.4% versus 0% with placebo 2.
You must:
- Monitor closely for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior 2
- Advise families and caregivers about the need for close observation 2
- Watch for agitation, irritability, self-harming, or unusual behavior, particularly in the first months of treatment or after dose changes
Drug Interaction Concerns
Bupropion is a CYP2D6 inhibitor 3, which theoretically could increase atomoxetine levels (atomoxetine is metabolized by CYP2D6). This interaction could:
- Increase atomoxetine exposure and side effects
- Require lower atomoxetine dosing than typical
- Necessitate more careful titration and monitoring
Practical Dosing Strategy
If you proceed with this combination:
- Start with atomoxetine monotherapy first at 0.5 mg/kg/day, titrating to therapeutic doses over 3-4 weeks
- Assess response after 4-6 weeks of adequate atomoxetine dosing
- If partial response, consider adding low-dose bupropion (start 150 mg/day extended-release)
- Titrate slowly given the CYP2D6 interaction concern
- Monitor cardiovascular parameters at each dose adjustment
- Watch for psychiatric symptoms intensively during the first 8 weeks
Common Pitfalls to Avoid
- Don't use this as first-line therapy – stimulants remain the gold standard with the strongest evidence 1
- Don't skip cardiovascular screening – both drugs affect heart rate and blood pressure 1
- Don't ignore the suicidality risk – atomoxetine's black box warning applies regardless of combination use 2
- Don't forget the CYP2D6 interaction – bupropion may increase atomoxetine levels 3
- Don't use in patients with seizure disorders – bupropion lowers seizure threshold 3
The Evidence Gap
The combination of bupropion plus atomoxetine specifically lacks high-quality evidence. While atomoxetine combinations with stimulants have "some limited evidence" 1, and bupropion monotherapy shows efficacy for ADHD 4, 5, no guideline or high-quality study directly addresses bupropion plus atomoxetine together. Recent systematic reviews on atomoxetine combinations focus on stimulants, not bupropion 6.
This combination represents off-label prescribing that should be documented carefully, with informed consent discussion about the limited evidence base and potential risks.